In addition to the liverfunctiontest, DFA is developing tests for milk spoilage and cow pregnancy, which it hopes to test in Kenya with an East African dairy collective.
The most common adverse reactions in patients treated with KYNAMRO that led to treatment discontinuation and occurred at a rate greater than placebo were: injection site reactions (5.0%), alanine aminotransferase (ALT) increased (3.4%), flu-like symptoms (2.7%), aspartate aminotransferase (AST) increased (2.3%), and liverfunctiontest abnormal (1.5%).
